Cartiva, Inc.
Timothy J. Patrick, President and CEO

Cartiva, Inc. develops and markets innovative products for the treatment of cartilage damage and osteoarthritis. Cartiva received Premarket Approval from the FDA on July 1, 2016 for its Cartiva Synthetic Cartilage Implant (SCI) for arthritis of the big toe joint.  The approval allows Cartiva to market the first synthetic cartilage device approved by the FDA in the US, and is supported by Level 1 clinical evidence from the largest randomized study ever conducted for this condition. Cartiva SCI is a biocompatible, biomedical polymer implant designed to offer an alternative to fusion by replacing damaged cartilage with a compressible, low-friction and durable bearing surface, thereby providing not only pain relief but also improved function and motion.